Toceranib phosphate is a multitargeted indolinone receptor tyrosine kinase (RTK) inhibitor with Kis of 5 and 6 nM for PDGFRβ and Flk-1/KDR, respectively.
|Solubility (25°C)||DMSO 2 mg/mL
Water 2 mg/mL
Powder -20°C 3 years ; 4°C 2 years
In solvent -80°C 6 months ; -20°C 1 month
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
 Sabina Sheppard-Olivares, et al. Vet Rec Open. Toceranib phosphate in the management of canine insulinoma: A retrospective multicentre study of 30 cases (2009-2019)
 Petros Frezoulis, et al. Vet Comp Oncol. The role of toceranib phosphate in dogs with non-mast cell neoplasia: A systematic review
 Hiroki Yamazaki, et al. J Vet Intern Med. Assessment of postoperative adjuvant treatment using toceranib phosphate against adenocarcinoma in dogs
 Felicia H Lew, et al. Vet Comp Oncol. Retrospective evaluation of canine heart base tumours treated with toceranib phosphate (Palladia): 2011-2018
 C London, et al. Vet Comp Oncol. Preliminary evidence for biologic activity of toceranib phosphate (Palladia(®)) in solid tumours
|Related VEGFR/PDGFR Products|
Pegdinetanib (BMS-844203; CT-322) is a selective VEGFR-2 (VEGFR) inhibitor with Kds of 11 nM and 250 nM and IC50s of 16 nM and 240 nM for human and murine VEGFR-2, respectively. Pegdinetanib does not bind to VEGFR-1 or VEGFR-3. Pegdinetanib has antitumor activity.
Sozinibercept (OPT 302; VGX-300) is a soluble form of VEGFR-3, potently inhibits the activity of VEGF-C/D, which are the proangiogenic factors, inhibiting angiogenesis and vascular leakage. Sozinibercept also inhibits diabetic retinal edema in rats.
Pulocimab is an anti-VEGFR2 monoclonal antibody (mAb). Pulocimab can be used for the research of cancers.
Tarcocimab (OG1953) is a humanized anti-VEGFA monoclonal antibody (IgG1 type). Tarcocimab is available for research in retinal vein occlusion (RVO) and wet age-related macular degeneration (AMD).
Efdamrofusp alfa is a bispecific fusion protein. Efdamrofusp alfa is capable of neutralizing both VEGF isoforms and C3b/C4b. Efdamrofusp alfa can be used for the research of neovascular age-related macular degeneration (nAMD) and other complement-related ocular conditions.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.